Modeling the potential impact of incretin-based therapies as weight-loss and diabetes treatments on population morbidity and mortality trends The RGA model Quantifying potential impacts of incretin-based therapies on mortality and morbidity outcomes is difficult, given the many uncertainties at play
For more information, see types of GLP1 drugs & brands
Since metformin improves the action of insulin and Ozempic promotes the secretion of insulin, they may have almost a synergistic effect, Pannain says
Several chemotherapies, particularly platinum-based chemotherapies, were excluded due to insufficient EMA product information
J Endocrinol Invest 42:11251131 Paccou J, Yavropoulou MP, Naciu AM, Chandran M, Messina OD, Rolvien T, Carey JJ, Doronzo S, Anastasilakis AD, Saag KG, Lems WF (2024) Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society
Targeting astrocytes in major depression